Investigational drug · Phase 3
Fianlimab
Also called: REGN3767
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
41
Any phase or sponsor naming "Fianlimab"
First trial start
2019
Jul 23, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fianlimab", any sponsor or status.
- Phase 232
Conditions studied
As listed on its trial records.
- Melanoma
- Non-small Cell Lung Cancer
- Hepatocellular Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Advanced Non-Small Cell Lung Cancer
- Locally Advanced Basal Cell Carcinoma
- Resectable Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Fianlimab" as an intervention, largest first.
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05608291 · 1,564 participants · Start Jan 16, 2023 · Primary completion Jan 15, 2027
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; San Francisco, California; Santa Monica, California · 211 sites in all
- Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05352672 · 1,546 participants · Start Jul 14, 2022 · Primary completion Mar 12, 2026
Drug: Fianlimab; Cemiplimab and 2 more · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; Orlando, Florida · 210 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04590326 · 612 participants (planned) · Start Dec 8, 2020 · Primary completion Nov 8, 2028
Drug: REGN5668; Cemiplimab and 3 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer and 1 more
Sites: Duarte, California; Irvine, California; Orange, California · 28 sites in all
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06246916 · 560 participants (planned) · Start Sep 9, 2024 · Primary completion Mar 22, 2027
Drug: fianlimab; cemiplimab and 1 more · For: Melanoma
Sites: Chandler, Arizona; Gilbert, Arizona; Tucson, Arizona · 113 sites in all
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06787612 · 397 participants (planned) · Start May 28, 2025 · Primary completion Jun 30, 2028
Drug: Ubamatamab; Bevacizumab and 5 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 56 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03005782 · 333 participants · Start Nov 7, 2016 · Primary completion Apr 2, 2024
Drug: REGN3767; cemiplimab · For: Malignancies
Sites: Encinitas, California; Fresno, California; La Jolla, California · 43 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05137054 · 317 participants (planned) · Start Aug 17, 2022 · Primary completion Mar 25, 2028
Drug: Linvoseltamab; Daratumumab and 9 more · For: Multiple Myeloma
Sites: La Jolla, California; Atlanta, Georgia; Indianapolis, Indiana · 42 sites in all
- A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06161441 · 195 participants · Start Jul 16, 2024 · Primary completion Aug 24, 2026
Drug: Fianlimab; Cemiplimab and 5 more · For: Resectable Non-small Cell Lung Cancer
Sites: Clermont, Florida; Chicago, Illinois; Westwood, Kansas · 123 sites in all
- A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05800015 · 160 participants · Start Aug 8, 2023 · Primary completion Jan 16, 2030
Drug: fianlimab; cemiplimab and 5 more · For: Non-small Cell Lung Cancer
Sites: Tucson, Arizona; Yuma, Arizona; Cerritos, California · 76 sites in all
- A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06190951 · 151 participants · Start Sep 18, 2024 · Primary completion Nov 2, 2026
Drug: cemiplimab; Fixed Dose Combination (FDC) cemiplimab+fianlimab and 1 more · For: Melanoma
Sites: La Jolla, California; Los Angeles, California; Newport Beach, California · 104 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Isaacs C, Nanda R, Yau C, et al. · JAMA Oncol 2026
- EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.
Saeed A, Yothers G, Puhalla SL, et al. · Future Oncol 2026
- Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
Kim TM, Williamson SK, Papadopoulos KP, et al. · Cancer 2026
- Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy.
Ghasemi K · Pathol Res Pract 2025
- First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Lakhani NJ, Papadopoulos KP, Johnson ML, et al. · Clin Cancer Res 2024
- Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements.
Martínez-Pérez A, Granda-Díaz R, Aguilar-García C, et al. · Biomark Res 2024
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.